VivoSeq
Oncology

Esophageal Adenocarcinoma

88

Pipeline Programs↗

27

Active Trials↗

36

Companies Involved↗

Esophageal Adenocarcinoma is a moderately active landscape with 88 programs across 36 companies. The most active players are Takeda, Novartis, Beijing DCTY Biotech Co.,Ltd.. 1 therapy is approved with 16 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

69/100

Pipeline Velocity

27/100

Mech. Concentration

8/100

Completion Rate

57/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Takeda logo

Takeda

2 programs

Phase 1Novartis logo

Novartis

1 program

Phase 1B

Beijing DCTY Biotech Co.,Ltd.

1 program

Phase 1C

Calithera Biosciences, Inc

1 program

Phase 1Roche logo

Roche

6 programs

Phase 2Amgen logo

Amgen

5 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

71%

Small molecule

66 of 93 classified programs — the dominant modality here.

29%ALL OTHERSMonoclonal antibody2224%Antibody–drug conjugate22%Protein / enzyme22%Cell therapy11%

Small molecule leads; the ring shows all 93 classified programs, each share of the total. Modality classified for 99% of 96 pipeline programs.

Analysis

Trial Status

62

clinical trials

Completed16 · 26%
Recruiting16 · 26%
Terminated11 · 18%
Unknown status7 · 11%
Active, not recruiting7 · 11%
Not yet recruiting4 · 6%
Other1 · 2%

Clinical Trials

Trial Activity

62 trials

A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma
Recruiting·CChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.·Phase 2·NCT06767800·204 enrolled
Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma
Recruiting·—·Phase 2·NCT06044311·25 enrolled
Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma
Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT05041153·15 enrolled
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
Recruiting·RRoswell Park Cancer Institute·Phase 2·NCT04682158·106 enrolled
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
Recruiting·CCanadian Cancer Trials Group·Phase 2·NCT06043427·168 enrolled
Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy
Recruiting·AAmsterdam UMC, location VUmc·Phase 2·NCT06687876·14 enrolled
Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma
Recruiting·UUNICANCER·Phase 2·NCT06846346·88 enrolled
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Recruiting·—·Phase 2·NCT04069273·58 enrolled
Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery
Recruiting·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT05713838·32 enrolled
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Recruiting·AbbVie logoAbbVie·Phase 2·NCT06628310·180 enrolled
RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2
Recruiting·—·Phase 1/2·NCT05403242·42 enrolled
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Recruiting·Merck & Co. logoMerck & Co.·Phase 1/2·NCT06469944·160 enrolled
ROSETTA Gastric-204: A Blinded, Randomized, Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Preclinical·NCT07221149·690 enrolled
Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer
Recruiting·NRG Oncology·Phase 3·NCT03801876·300 enrolled
Determination of Minimal Residual Disease by Deep ctDNA Sequencing.
Recruiting·MMasaryk Memorial Cancer Institute·Preclinical·NCT07660627·34 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)